Metformin and pioglitazone: effectively treating insulin resistance

References

• Nigro J, Osman N, Dart AM, et al. Insulin resistance and atherosclerosis. Endocr Rev 2006;27:242–59
   PubMed Web of Science ®Google Scholar
• Krentz AJ, Bailey CJ. Oral antidiabetic agents. Current role in type 2 diabetes mellitus. Drugs 2005;65:385–411
   Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998:352: 854–65
   Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, et al.; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366: 1279–89
   Google Scholar
• Kahn SE. The relative contributions of insulin resistance and beta cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003;46:3–19
   PubMed Web of Science ®Google Scholar
• Bailey CJ. Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Diabetes Obes Metab 2005;7:675–91
   PubMed Web of Science ®Google Scholar
• Barroso I. Genetics of type 2 diabetes. Diabet Med 2005;22:517–35
   PubMed Web of Science ®Google Scholar
• Ferrannini E. Is insulin resistance the cause of the metabolic syndrome? Ann Med 2006;38:42–51
   PubMed Web of Science ®Google Scholar
• Matthaei S, Stumvoll M, Kellerer M, et al. Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev 2000;21:585–618
   PubMed Web of Science ®Google Scholar
• Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am 2004;33:283–303
   PubMed Web of Science ®Google Scholar
• Basu R, Basu A, Johnson CM, et al. Insulin dose-response curves for stimulation of splanchnic glucose uptake and suppression of endogenous glucose production differ in nondiabetic humans and are abnormal in people with type 2 diabetes. Diabetes 2004;53:2042–50
   PubMed Web of Science ®Google Scholar
• Lewis GF, Carpentier A, Adeli K, et al. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002;23:201–29
   PubMed Web of Science ®Google Scholar
• Duckworth WC, Bennett RG, Hamel FG. Insulin degradation: progress and potential. Endocrine Rev 1998;19:608–24
   Google Scholar
• Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004;89: 463–78
   Google Scholar
• Kahn SE. Clinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001;86:4047–58
   PubMed Web of Science ®Google Scholar
• Buchanan TA. Prevention of type 2 diabetes. What is it really? Diabetes Care 2003;26:1306–8
   PubMed Web of Science ®Google Scholar
• Evans JL, Goldfine ID, Maddux BA, et al. Are oxidative stress-activated signalling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes 2003;52:1–8
   PubMed Web of Science ®Google Scholar
• Rhodes CJ. Type 2 diabetes – a matter of beta-cell life and death? Science 2005;307:380–4
   PubMed Web of Science ®Google Scholar
• Natali A, Toschi E, Baldeweg S, et al. Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes. Diabetes 2006;55:1133–40
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106–18
   PubMed Web of Science ®Google Scholar
• Miyazaki Y, Mahankali A, Wajcberg E, et al. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2004;89:4312–9
   PubMed Web of Science ®Google Scholar
• Harte AL, McTernan PG, McTernan CL, et al. Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes. Diabetes Obes Metab 2003;5:302–10
   PubMed Web of Science ®Google Scholar
• Di Gregorio GB, Yao-Borengasser A, Rasouli N, et al. Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes 2005;54:2305–13
   PubMed Web of Science ®Google Scholar
• Hammarstedt A, Andersson CX, Rotter Sopasakis V, et al. The effect of PPARg ligands on the adipose tissue in insulin resistance. Prostaglandins Leukot Essent Fatty Acids 2005;73:65–75
   PubMed Web of Science ®Google Scholar
• Harte A, McTernan P, Chetty R, et al. Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone. Circulation 2005;111:1954–61
   PubMed Web of Science ®Google Scholar
• Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002;87:2784–91
   PubMed Web of Science ®Google Scholar
• de Souza CJ, Eckhardt M, Gagen K, et al. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 2001;50:1863–71
   PubMed Web of Science ®Google Scholar
• Bouskila M, Pajvani UB, Scherer PE. Adiponectin: a relevant player in PPARgamma-agonist-mediated improvements in hepatic insulin sensitivity? Int J Obes Relat Metab Disord 2005;29:S17–23
   Google Scholar
• Kubota N, Terauchi Y, Kubota T, et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin dependent and independent pathway. J Biol Chem 2006;281:8748–55
   PubMed Web of Science ®Google Scholar
• Nawrocki AR, Rajala MW, Tomas E, et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 2006;281:2654–60
   PubMed Web of Science ®Google Scholar
• Bajaj M, Suraamornkul S, Pratipanawatr T, et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 2003;52:1364–70
   PubMed Web of Science ®Google Scholar
• Matsuura B, Kanno S, Minami H, et al. Effects of antihyperlipidemic agents on hepatic insulin sensitivity in perfused Goto-Kakizaki rat liver. J Gastroenterol 2004;39:339–45
   PubMed Web of Science ®Google Scholar
• Tiikkainen M, Häkkinen AM, Korsheninnikova E, et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004;53:2169–76
   PubMed Web of Science ®Google Scholar
• Bajaj M, Suraamornkul S, Hardies LJ, et al. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes Relat Metab Disord 2004;28:783–9
   PubMed Web of Science ®Google Scholar
• Bajaj M, Suraamornkul S, Piper P, et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 2004;89:200–6
   PubMed Web of Science ®Google Scholar
• Rasouli N, Raue U, Miles LM, et al. Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Am J Physiol Endocrinol Metab 2005;288:E930–4
   PubMed Web of Science ®Google Scholar
• Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167–74
   PubMed Web of Science ®Google Scholar
• Musi N, Hirshman MF, Nygren J, et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002;51:2074–81
   PubMed Web of Science ®Google Scholar
• Kahn BB, Alquier T, Carling D, et al. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005;1:15–25
   PubMed Web of Science ®Google Scholar
• Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005;310:1642–6
   PubMed Web of Science ®Google Scholar
• Carling D. LKB1: a sweet side to Peutz-Jeghers syndrome? Trends Mol Med 2006;12:144–7
   PubMed Web of Science ®Google Scholar
• Fryer LG, Parbu-Patel A, Carling D. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 2002;277:25226–32
   PubMed Web of Science ®Google Scholar
• Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:550–4
   PubMed Web of Science ®Google Scholar
• Ikeda T, Iwata K, Murakami H. Inhibitory effect of metformin on intestinal glucose absorption in the perfused rat intestine. Biochem Pharmacol 2000;59:887–90
   Google Scholar
• Klein J, Westphal S, Kraus D, et al. Metformin inhibits leptin secretion via a mitogen-activated protein kinase signalling pathway in brown adipocytes. J Endocrinol 2004;183:299–307
   PubMed Web of Science ®Google Scholar
• Natali A, Ferrannini E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 2006;49:434–41
   PubMed Web of Science ®Google Scholar
• Sreenan S, Sturis J, Pugh W, et al. Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone. Am J Physiol 1996;271:E742–7
   PubMed Web of Science ®Google Scholar
• Patanè G, Piro S, Rabuazzo AM, et al. Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells. Diabetes 2000;49:735–40
   Google Scholar
• Lupi R, Del Guerra S, Fierabracci V, et al. Lipotoxicity in human pancreatic islets and the protective effect of metformin. Diabetes 2002;51:S134–7
   PubMed Web of Science ®Google Scholar
• Lupi R, Del Guerra S, Marselli L, et al. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion. Am J Physiol Endocrinol Metab 2004;286:E560–7
   PubMed Web of Science ®Google Scholar
• Diani AR, Sawada G, Wyse B, et al. Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes. Am J Physiol Endocrinol Metab 2004;286:E116–22
   PubMed Web of Science ®Google Scholar
• Zeender E, Maedler K, Bosco D, et al. Pioglitazone and sodium salicylate protect human beta-cells against apoptosis and impaired function induced by glucose and interleukin-1beta. J Clin Endocrinol Metab 2004;89:5059–66
   PubMed Web of Science ®Google Scholar
• Wallace TM, Levy JC, Matthews DR. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Diabet Med 2004;21:568–76
   Google Scholar
• Urquhart R, Tan MH, Mariz S, et al. Long-term (2-year) effects on HOMA-%S, an estimate of insulin sensitivity, of pioglitazone, gliclazide and metformin as add-on therapies in patients with T2DM. Diabetes 2004;53:A150 [abstract]
   Google Scholar
• Juhl CB, Hollingdal M, Porksen N, et al. Influence of rosiglitazone treatment on beta-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility. J Clin Endocrinol Metab 2003;88:3794–800
   PubMed Web of Science ®Google Scholar
• Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic b-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002;51:2796–803
   PubMed Web of Science ®Google Scholar
• Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346: 393–403
   Google Scholar
• Knowler WC, Hamman RF, Edelstein SL, et al; Diabetes Prevention Program. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005;54: 1150–6
   Google Scholar
• Xiang AH, Peters RK, Kjos SL, et al. Pharmacological treatment of insulin resistance at two different stages in the evolution of type 2 diabetes: impact on glucose tolerance and beta-cell function. J Clin Endocrinol Metab 2004;89:2846–51
   PubMed Web of Science ®Google Scholar
• Xiang AH, Peters RK, Kjos SL, et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006;55:517–22
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995;333:541–9
   PubMed Web of Science ®Google Scholar
• Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997;103:491–7
   PubMed Web of Science ®Google Scholar
• Yale JF, Valiquett TR, Ghazzi MN, et al. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;134:737–45
   Google Scholar
• Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001;111:10–7
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Shen SG, Gatlin MR, et al. Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes. Diabetes Care 2002;25:1529–33
   PubMed Web of Science ®Google Scholar
• Baksi A, James RE, Zhou B, et al. Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylurea. Acta Diabetol 2004;41:63–9
   PubMed Web of Science ®Google Scholar
• Herz M, Johns D, Reviriego J, et al. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antiglycemic medication-naive patients with type 2 diabetes mellitus. Clin Ther 2003;25:1074–95
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Brunetti P, Schernthaner GH, et al.; QUARTET Study Group. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004;27: 141–7
   Google Scholar
• Kerenyi Z, Samer H, James R, et al. Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2004;63:213–23
   PubMed Web of Science ®Google Scholar
• Tan M, Johns D, Gonzalez Galvez G, et al.; GLAD Study Group. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial. Clin Ther 2004a;26: 680–93
   Google Scholar
• Tan MH, Johns D, Strand J, et al; GLAC Study Group. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with type 2 diabetes. Diabet Med 2004b;21: 859–66
   Google Scholar
• Charbonnel BH, Matthews DR, Schernthaner G, et al.; QUARTET Study Group. A long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med 2005a;22: 399–405
   Google Scholar
• Pavo I, Jermendy G, Varkonyi TT, et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab 2003;88:1637–45
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Matthews DR, Charbonnel B, et al.; QUARTET Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004;89: 6068–76
   Google Scholar
• Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000;22:1395–409
   Google Scholar
• Charbonnel B, Schernthaner G, Brunetti P, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005;48:1093–104
   PubMed Web of Science ®Google Scholar
• Weissman P, Goldstein BJ, Rosenstock J, et al. Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study. Curr Med Res Opin 2005;21:2029–35
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Bagdonas A, Rubes J, et al. Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study. Clin Ther 2005;27:1548–61
   PubMed Web of Science ®Google Scholar
• Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003;46:733–49
   PubMed Web of Science ®Google Scholar
• Buse JB, Tan MH, Prince MJ, et al. The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab 2004;6:133–56
   PubMed Web of Science ®Google Scholar
• Chu NV, Kong AP, Kim DD, et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care 2002;25:542–9
   PubMed Web of Science ®Google Scholar
• Lawrence JM, Reid J, Taylor GJ, et al. Favorable effects of pioglitazone and metformin compared with gliclazide on lipo-protein subfractions in overweight patients with early type 2 diabetes. Diabetes Care 2004;27:41–6
   PubMed Web of Science ®Google Scholar
• Perez A, Khan M, Johnson T, et al. Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes. Diab Vasc Dis Res 2004;1:44–50
   PubMedGoogle Scholar
• Freed MI, Ratner R, Marcovina SM, et al; Rosiglitazone Study 108 investigators. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 2002;90: 947–52
   Google Scholar
• Goldberg RB, Kendall DM, Deeg MA, et al; GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28: 1547–54
   Google Scholar
• Betteridge DJ, Vergés B. Long-term effects on lipids and lipo-proteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes. Diabetologia 2005;48:2477–81
   PubMed Web of Science ®Google Scholar
• Mäkimattila S, Nikkila K, Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus. Diabetologia 1999; 42:406–12
   Google Scholar
• Havel PJ. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol 2002;13:51–9
   PubMed Web of Science ®Google Scholar
• Havel PJ. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes 2004;53:S143–51
   PubMed Web of Science ®Google Scholar
• Rajala MW, Scherer PE. Minireview: the adipocyte – at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003;144:3765–73
   PubMed Web of Science ®Google Scholar
• Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem 2004;50:1511–25
   PubMed Web of Science ®Google Scholar
• Kim YW, Kim JY, Park YH, et al. Metformin restores leptin sensitivity in high-fat-fed obese rats with leptin resistance. Diabetes 2006;55:716–24
   PubMed Web of Science ®Google Scholar
• Kay JP, Alemzadeh R, Langley G, et al. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 2001;50:1457–61
   PubMed Web of Science ®Google Scholar
• Rasouli N, Yao-Borengasser A, Miles LM, et al. Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression. Am J Physiol Endocrinol Metab 2006;290:E42–6
   PubMed Web of Science ®Google Scholar
• Hollenberg NK. Considerations for management of fluid dynamic issues associated with thiazolidinediones. Am J Med 2003;115:111S–5S
   Google Scholar
• Smith SR, De Jonge L, Volaufova J, et al. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism 2005;54:24–32
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557–65
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cannon CP, Morrow D, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20–8
   Google Scholar
• Wang TD, Chen WJ, Lin JW, et al. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol 2004;93:362–5
   PubMed Web of Science ®Google Scholar
• Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679–84
   PubMed Web of Science ®Google Scholar
• Satoh N, Ogawa Y, Usui T, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003;26:2493–9
   PubMed Web of Science ®Google Scholar
• De Jager J, Kooy A, Lehert P, et al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med 2005;257:100–9
   PubMed Web of Science ®Google Scholar
• Pfutzner A, Marx N, Lubben G, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005;45:1925–31
   PubMed Web of Science ®Google Scholar
• Abbasi F, Chu JW, McLaughlin T, et al. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism 2004;53:159–64
   PubMed Web of Science ®Google Scholar
• Dandona P, Aljada A, Ghanim H, et al. Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. J Clin Endocrinol Metab 2004;89:5043–7
   PubMed Web of Science ®Google Scholar
• Sobel BE, Woodcock-Mitchell J, Schneider DJ, et al. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation 1998;97:2213–21
   PubMed Web of Science ®Google Scholar
• Derosa G, Cicero AF, Gaddi A, et al. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract 2005;69:5–13
   PubMed Web of Science ®Google Scholar
• Langenfeld MR, Forst T, Hohberg C, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005;111:2525–31
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Sera Y, Abe Y, et al. Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes. Diabetes Res Clin Pract 2004;64:225–8
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Del Prato S, Eddy D, et al.; Global Partnership for Effective Diabetes Management. Earlier intervention in type 2 diabetes: the case for achieving early and sustained glycaemic control. Int J Clin Pract 2005;59: 1309–16
   Google Scholar
• International Diabetes Federation Clinical Guidelines Task Force 2005. Global Guideline for Type 2 Diabetes [online]. Available from http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf [Last accessed 11 May 2006]
   Google Scholar
• Canadian Diabetes Association 2003. Canadian Diabetes Association. Clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003;27:S1–152 [online]. Available from http://www.diabetes.ca/cpg2003/downloads/cpgcomplete.pdf [Last accessed 11 May 2006]
   Google Scholar
• ACE/AACE Diabetes Road Map Task Force 2005. Road map for the prevention and treatment of type 2 diabetes [online]. Available from http://www.aace.com/meetings/consensus/odimplementation/roadmap.pdf [Last accessed 11 May 2006]
   Google Scholar